Keyphrases
Hormonal Regulation
100%
Human Breast Cancer Cell Lines
100%
Plasminogen Activator
100%
Estrogen Receptor
44%
Estrogen
27%
Urokinase
27%
Estradiol
22%
MCF-7 Cells
16%
Human Breast Cancer Cells
11%
4-fold
11%
Molecular Mass
11%
L-cells
11%
MDA-MB-231 Cells
11%
ZR-75-1
11%
Active Sites
5%
Incubation
5%
Conditioned Medium
5%
Human Breast Cancer
5%
MCF-7
5%
Estrogenic Activity
5%
Zymography
5%
Competitive Inhibitor
5%
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
5%
Urokinase-type Plasminogen Activator
5%
Physiological Concentrations
5%
Receptor System
5%
Serum-free
5%
Dose-response Curve
5%
Estrogen Action
5%
Delta Cell
5%
Hormone Responsiveness
5%
Tissue Plasminogen Activator (t-PA)
5%
Co-cultivation
5%
Endocrine Therapy
5%
SDS-polyacrylamide Gel
5%
Neuroblastoma Cells
5%
Functional Receptor
5%
Medicine and Dentistry
Breast Cancer Cell Line
100%
Hormonal Regulation
100%
Plasminogen Activator
100%
Estrogen Receptor
44%
Urokinase
33%
Diethylstilbestrol
22%
MCF-7
22%
Cell Line
16%
Breast Cancer
16%
Cancer Cell
11%
Parathion
11%
Receptor
5%
Incubation
5%
Zymography
5%
Hormone Therapy
5%
Competitive Inhibition
5%
Dose Response
5%
Polyacrylamide Gel Electrophoresis
5%
Polyacrylamide Gel
5%
Somatostatin Cell
5%
Estrogen Activity
5%
Hormone Response
5%
Tissue Plasminogen Activator
5%
Neuroblastoma Cell
5%
4 Aminobenzamidine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Plasminogen Activator
100%
Estrogen Receptor
44%
Urokinase
33%
Diethylstilbestrol
22%
Parathion
11%
Receptor
5%
Polyacrylamide Gel
5%
Polyacrylamide Gel Electrophoresis
5%
Competitive Inhibitor
5%
Endocrine Therapy
5%
4 Aminobenzamidine
5%
Tissue Plasminogen Activator
5%
Neuroblastoma
5%
Neuroscience
Cell Line
100%
Plasminogen Activator
100%
Estrogen Receptor
44%
Urokinase
33%
Diethylstilbestrol
22%
Eicosanoid Receptor
5%
Neuroblastoma
5%
Zymography
5%
Competitive Inhibition
5%
Polyacrylamide
5%
Somatostatin Cell
5%
Polyacrylamide Gel Electrophoresis
5%
Hormone Therapy
5%
Tissue Plasminogen Activator
5%